
Nola Hylton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11034903/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic Architectural and Dynamic Features at Breast MR Imaging: Multicenter Study. Radiology, 2006, 238, 42-53.	7.3	469
2	Magnetic Resonance Imaging of the Breast Prior to Biopsy. JAMA - Journal of the American Medical Association, 2004, 292, 2735.	7.4	443
3	Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology, 2012, 30, 3242-3249.	1.6	379
4	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker. Journal of Clinical Oncology, 2006, 24, 3293-3298.	1.6	374
5	Utility of Magnetic Resonance Imaging in the Management of Breast Cancer: Evidence for Improved Preoperative Staging. Journal of Clinical Oncology, 1999, 17, 110-110.	1.6	371
6	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 2012, 132, 1049-1062.	2.5	286
7	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. Annals of Surgical Oncology, 2001, 8, 549-559.	1.5	185
8	Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Research and Treatment, 2010, 119, 137-144.	2.5	179
9	Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Research, 2016, 76, 5933-5944.	0.9	105
10	Contrastâ€Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast Journal, 1999, 5, 13-21.	1.0	103
11	Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Annals of Surgical Oncology, 2013, 20, 3823-3830.	1.5	87
12	Magnetic Resonance Imaging of the Breast: Opportunities to Improve Breast Cancer Management. Journal of Clinical Oncology, 2005, 23, 1678-1684.	1.6	67
13	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncology, The, 2012, 13, e240-e248.	10.7	64
14	Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. Journal of Biomedical Optics, 2005, 10, 051503.	2.6	60
15	Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. American Journal of Surgery, 2006, 192, 520-524.	1.8	46
16	MRI in breast cancer therapy monitoring. NMR in Biomedicine, 2011, 24, 712-720.	2.8	42
17	MR Imaging for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy. Magnetic Resonance Imaging Clinics of North America, 2006, 14, 383-389.	1.1	40
18	Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. Scientific Reports, 2019, 9, 12114.	3.3	40

Nola Hylton

#	Article	IF	CITATIONS
19	The Impact of Preoperative Magnetic Resonance Imaging on Surgical Treatment and Outcomes for Ductal Carcinoma In Situ. Clinical Breast Cancer, 2011, 11, 33-38.	2.4	39
20	Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. Journal of Biomedical Optics, 2018, 24, 1.	2.6	32
21	How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World Journal of Clinical Cases, 2015, 3, 607.	0.8	20
22	Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography, 2016, 2, 378-387.	1.8	20
23	Integration of breast imaging into cancer management. Current Oncology Reports, 2000, 2, 572-581.	4.0	2
24	MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer. Annals of Surgical Oncology, 2001, 8, 549-559.	1.5	2
25	Seminars in Oncology: The Emerging Role of MRI in Neoadjuvant Therapy. Seminars in Breast Disease, 2004, 7, 75-78.	0.0	0
26	Magnetic Resonance Imaging and Neoadjuvant Chemotherapy. , 2017, , 103-120.		0